Cas:39086-05-0 ethyl 3-bromo-4-oxocyclohexane-1-carboxylate manufacturer & supplier

Chemical Name:ethyl 3-bromo-4-oxocyclohexane-1-carboxylate

CAS.NO:39086-05-0

Synonyms:3-bromo-4-ketocyclohexanecarboxylic acid ethyl ester;3-bromo-4-oxocyclohexanecarboxylic acid ethyl ester;ETHYL 3-BROMO-4-OXOCYCLOHEXANECARBOXYLATE;Cyclohexanecarboxylic acid,3-bromo-4-oxo-,ethyl ester

Molecular Formula:C₉H₁₃BrO₃

Molecular Weight:249.10200

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:43.37000

Exact Mass:248.00500

LogP:1.68220

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-bromo-4-ketocyclohexanecarboxylic acid ethyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Cyclohexanecarboxylic acid,3-bromo-4-oxo-,ethyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-bromo-4-ketocyclohexanecarboxylic acid ethyl ester Use and application,3-bromo-4-oxocyclohexanecarboxylic acid ethyl ester technical grade,usp/ep/jp grade.

Related News: The program will run alongside our ongoing Phase 3 INSPIRE Trial, and is expected to continue until commercial launch in such countries. ethyl 3-bromo-4-oxocyclohexane-1-carboxylate manufacturer Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: ��Within the top 20 global companies that spent the most on R&D in 2018, the top spender �C despite having the second smallest annual revenue of the group at $15.28 billion �C is Celgene, whose R&D spend was equal to 37% of its annual revenue. ethyl 3-bromo-4-oxocyclohexane-1-carboxylate supplier Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity. ethyl 3-bromo-4-oxocyclohexane-1-carboxylate vendor Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: ��Within the top 20 global companies that spent the most on R&D in 2018, the top spender �C despite having the second smallest annual revenue of the group at $15.28 billion �C is Celgene, whose R&D spend was equal to 37% of its annual revenue. ethyl 3-bromo-4-oxocyclohexane-1-carboxylate factory But Sanofi’s rival CD38 antibody Sarclisa may soon be able to challenge Darzalex in the same front-line, transplant-ineligible population with the help of a more powerful backbone.